Cytokinetics, Inc. (CYTK)
63.89
-8.92%
Cytokinetics, Inc. (CYTK) is currently trading at $63.89. This represents a loss of 8.92% from the previous session. With a market capitalization of $7.80B, CYTK is a key component of the Health Care sector. Investors looking to trade CYTK should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Claim Your $300 Cash Bonus →
T&Cs Apply. Trade CYTK commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Cytokinetics, Inc. (CYTK) shows a bearish trend. Analysts are watching the 69.28 level closely.
Fundamentals
Mkt Cap7.80B
P/E Ratio0.0000
Volume2,203,402
60-Day Technical Chart
Advanced Charting
Need more indicators for CYTK? Use the world's #1 platform.
Open CYTK on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $64
| Metric |
CYTK -8.92% |
FCX +2.09% |
BMY -0.86% |
AA +6.69% |
|---|---|---|---|---|
| Price | $63.89 | $69.33 | $61.07 | $65.56 |
| Mkt Cap | $7.80B | $99.66B | $124.37B | $16.97B |
| - | View → | View → | View → |
Latest Headlines
Cytokinetics (CYTK): Analyst Jason Butler Raises Price Target to $96 | CYTK Stock News
GuruFocus • Feb 25, 2026
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Powerhouse with 33% Potential Upside
DirectorsTalk Interviews • Feb 23, 2026
CYTK Sees Positive Analyst Ratings as Needham Raises Price Target | CYTK Stock News
GuruFocus • Feb 25, 2026
Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo
Zacks Investment Research • Feb 18, 2026
New heart drug MYQORZO approved to help adults with obstructive HCM symptoms
Stock Titan • Dec 19, 2025
● Gemini Agentic AI Analyst Insight for CYTK
Market Education
- From Small Players to Market Movers: How Former Small Caps Are Scaling Up Sep 27, 2025
- Government Shutdowns: What They Mean for Wall Street Sep 26, 2025
- Candlestick Patterns every trader should know Apr 20, 2021
External Research